Q2 2026 Veru Inc Earnings Call Transcript

May 13, 2026 / 12:00 PM GMT

Release Date Price: $2.26 (-0.44%)

Transcript 10-Q8-K

Key Points

Positve

Veru Inc (VERU) has completed a positive Phase IIb clinical trial demonstrating that their drug, enovasarm, combined with a GLP-1 receptor agonist, preserves lean mass and enhances fat loss in older patients with obesity.
The company is targeting a large market opportunity with over 1 billion people globally affected by obesity, and a significant portion of these are older adults with sarcopenic obesity.
Research and development costs have decreased, indicating efficient management of resources as the Phase IIb clinical study winds down.
Veru Inc (VERU) has a strong cash position with $27.6 million in cash equivalents and restricted cash, providing a financial cushion for ongoing operations.
The company successfully raised $23.4 million through a public offering, enhancing its financial stability and ability to fund future clinical studies.

Negative

Veru Inc (VERU) reported a net loss of $3.1 million for the quarter, indicating ongoing financial challenges.
The company is not yet profitable and continues to experience negative cash flows from operations.
There is uncertainty regarding the need for additional Phase III studies, which could delay the commercialization of their drug.
The market for obesity treatments is competitive, with only two companies currently treating a small percentage of the global population, posing a challenge for Veru Inc (VERU) to capture market share.
The company's future success is heavily dependent on the outcomes of ongoing and future clinical trials, which carry inherent risks and uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VERU.OQ - Veru Inc
Q2 2026 Veru Inc Earnings Call
May 13, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and welcome to Veroo Inc.'s Investors Conference Call.

All participants will be in a listen-only mode.

Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.

After this morning's discussion, there will be an opportunity to ask questions.

Please note that this event is being recorded.

I would now like to turn the conference over to Mr. Sam Fish, Veroux Inc.'s Executive Director, Investors Relations and Corporate Communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.